CVRx, Inc. (CVRX) research
CVRx, Inc.- Sector
- Healthcare
- Industry
- Medical Devices
- Last price
- $3.04
- As of
CVRx, Inc. (CVRX): 5 institutional managers tracked by Kresmion reported non-option positions in their 2026Q2 Form 13F filings, and the most recent SEC filing on record for the company is a Form 8-K filed 2026-08-11.
As of . Source: SEC EDGAR filings for CVRX. Method and limitations.
Share the CVRX intelligence card
See CVRX live in the terminal
Track CVRX's insider trades, 13F flows, options positioning, and cross asset confluence as they update, on one live board. Free account.
Open the live CVRX terminal, freeActive signals for CVRX
- highINSTITUTIONAL_SURGE
RENAISSANCE TECHNOLOGIES LLC added +1092% to CVRX (2026Q2)
- highINSTITUTIONAL_EXIT
CITADEL ADVISORS LLC cut 91% of CVRX (2026Q2)
- highINSTITUTIONAL_SURGE
RENAISSANCE TECHNOLOGIES LLC added +1092% to CVRX (2026Q2)
- highINSTITUTIONAL_EXIT
CITADEL ADVISORS LLC cut 91% of CVRX (2026Q2)
- highINSTITUTIONAL_SURGE
RENAISSANCE TECHNOLOGIES LLC added +1092% to CVRX (2026Q2)
FREE, NO ACCOUNT
Every signal on CVRX, as it fires
You are seeing 5 of 16 signals recorded on CVRX since 2026-05-30.
The five above landed across 2 days. The other 11 were recorded on 2 other days. 13 of the 16 are institutional flow rows, which arrive in batches on filing days.
No fixed schedule: it goes out when the data has something in it. Unsubscribe anytime. We never sell your data.
Largest reported share positions in CVRX (2026Q2)
| Manager / security | Market value | % portfolio | QoQ |
|---|---|---|---|
| RENAISSANCE TECHNOLOGIES LLCCUSIP 126638105 · 2026Q2 | $1.2M | 0.00% | , |
| TWO SIGMA INVESTMENTS, LPCUSIP 126638105 · 2026Q2 | $681K | 0.00% | , |
| CITADEL ADVISORS LLCCUSIP 126638105 · 2026Q2 | $406K | 0.00% | , |
| Point72 Asset Management, L.P.CUSIP 126638105 · 2026Q2 | $138K | 0.00% | , |
| MILLENNIUM MANAGEMENT LLCCUSIP 126638105 · 2026Q2 | $84K | 0.00% | , |
Quarterly SEC Form 13F disclosures from the managers Kresmion tracks, not a complete ownership ranking. Non-option holdings only; reported put and call positions are excluded. Different securities are labeled by CUSIP. Values are reporting-period snapshots, not current position values. Filings can arrive up to 45 days after quarter-end.
Recent SEC filings, CVRX
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-KSEC EDGAR ↗
CVRX against its peers
CVRX's operating margin of -90.5% ranks in the 38th percentile of 19 Medical Devices sub-industry peers, fiscal periods ending between 2025-12-31 and 2026-02-28.
| Metric | CVRX | Peer median | Percentile | n |
|---|---|---|---|---|
| Revenue FY | 56.7M USD | 32.0M USD | 73 | 19 |
| Gross margin | 85.3% | 52.7% | 91 | 15 |
| Operating margin | -90.5% | -55.8% | 38 | 19 |
| Net margin | -94.1% | -66.4% | 38 | 19 |
| Return on equity | -135.6% | -70.9% | 28 | 15 |
Peers (19): LUNG, SERA, ZOMDF, HYPR, ECOR, LNSR, OM, RPID, POSC, NNOX, MDNC, COCH, SRTS, MYO, MDAI, QTRX, XTNT, APYX, TELA. Left out: RTGN (no annual filing). Fiscal periods ending between 2025-12-31 and 2026-02-28. Every figure is one full fiscal year read from one annual filing (CVRX: 10-K), reported in USD. Nothing is trailing twelve months and nothing is converted between currencies. Source: SEC EDGAR XBRL company facts (public domain); prices from Kresmion's daily equity market-data snapshot. Open the full comparison.
Related tickers
See more CVRX signals as they fire
Kresmion publishes filings, 13F flows, on-chain whale activity, and cross-asset signals in real time. Open a live board scoped to CVRXand get the insider, 13F, options, and confluence read in one view.